)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Aligos Therapeutics
Aligos Therapeutics (ALGS) investor relations material
Aligos Therapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary7 May, 2026
Executive summary
Focused on developing therapeutics for liver diseases and viral infections, with three clinical-stage candidates: pevifoscorvir sodium (HBV), ALG-055009 (MASH/obesity), and ALG-097558 (coronavirus).
Pevifoscorvir sodium received FDA Fast Track Designation for chronic HBV infection; Phase 2 B-SUPREME trial ongoing with positive interim analysis and DSMB recommendation to increase sample size.
Entered an exclusive license with Amoytop for pevifoscorvir sodium in Greater China, receiving $25M upfront and eligibility for up to $420M in milestones and royalties.
ALG-055009 showed positive Phase 2a results in MASH, with significant liver fat reduction and favorable safety profile; funding and out-licensing options under evaluation.
IND-enabling studies for ALG-170675 (ASO for HBV) are underway, with development costs in China funded by Amoytop.
Financial highlights
Revenue from customers was $2.8M for Q1 2026, up from $0.3M in Q1 2025, driven by a milestone payment from Amoytop.
Net loss for Q1 2026 was $23.0M, or $(2.21) per share basic, compared to net income of $43.1M, or $5.12 per share basic, in Q1 2025.
Research and development expenses increased 61% year-over-year to $23.4M, mainly due to higher clinical trial costs for pevifoscorvir sodium.
General and administrative expenses rose 27% to $6.4M, reflecting higher personnel and legal costs.
Cash, cash equivalents, and short-term investments totaled $54.9M as of March 31, 2026.
Outlook and guidance
Current cash and expected Amoytop upfront payment are projected to fund operations into Q4 2026.
Additional capital will be required to continue operations beyond Q4 2026; management is actively seeking further financing.
Topline data from the Phase 2 B-SUPREME study for pevifoscorvir sodium anticipated in 2027, with a second interim analysis for the HBeAg+ cohort expected in H2 2026.
Long-term post-treatment data from Phase 1 study to be presented at EASL 2026 Congress.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aligos Therapeutics
- Annual meeting to vote on directors, auditor, stock plan amendment, and executive pay proposals.ALGS
Proxy filing29 Apr 2026 - Proxy seeks approval for director elections, auditor, ESPP amendment, and executive pay votes.ALGSProxy filing29 Apr 2026
- Pevifoscorvir sodium and ALG-055009 show strong clinical and commercial potential in HBV and MASH.ALGSCorporate presentation16 Apr 2026
- Pevifoscorvir sodium achieves superior HBV suppression and safety, with strong regulatory support.ALGSCorporate presentation23 Mar 2026
- Clinical and financial progress achieved, with pivotal HBV data expected in 2027.ALGSQ4 20255 Mar 2026
- Pevi delivers deep, durable HBV suppression with no resistance, setting a new clinical benchmark.ALGSJefferies London Healthcare Conference 20253 Feb 2026
- ALG-055009 achieved up to 46.2% liver fat reduction and favorable safety in MASH trials.ALGSStudy Result20 Jan 2026
- ALG-00184 delivers robust, resistance-free HBV suppression, surpassing current therapies.ALGS8th Annual MASH Investor Conference19 Jan 2026
- Global phase 2 hepatitis B study launches with best-in-class efficacy and major 2025 catalysts.ALGSPiper Sandler 36th Annual Healthcare Conference12 Jan 2026
Next Aligos Therapeutics earnings date
Q2 20264 Aug, 2026
Aligos Therapeutics
Next Aligos Therapeutics earnings date
Q2 20264 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage